"Reimbursement is a series of hurdles; it's a marathon."

- Roger Longman, CEO of consulting firm Real Endpoints LLC

"The success of the company going forward is going to be driven by many things – none more important than denosumab."

- Amgen Inc. CEO Kevin Sharer, during a recent business update

"While it could be that Dendreon's explanations ultimately prove true, and that Provenge's ramp is simply delayed, we are tired of making excuses for what has been a disappointing commercial trajectory since day 1 of launch."

- Eric Schmidt, analyst with Cowen and Co., on Dendreon Corp.'s second-quarter miss